Research graph
References from Asymmetric Complementarity: A Subtype-Specific Strategy via Visual Assessment of DCE-MRI and DWI for Evaluating NAT Efficacy in Breast Cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer statistics, 2025
2025 · External reference
Breast cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology
10.6004/jnccn.2022.0030 · 2022 · External reference
Surrogacy of pathologic complete response in trials of neoadjuvant therapy for early breast cancer: critical analysis of strengths, weaknesses, and misinterpretations
10.1001/jamaoncol.2022.3755 · 2022 · External reference
Breast MRI: state of the art
10.1148/radiol.2019182947 · 2019 · External reference
Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer
10.1007/s10549-012-2033-5 · 2012 · External reference
Diffusion-weighted MRI findings predict pathologic response in neoadjuvant treatment of breast cancer: the ACRIN 6698 multicenter trial
10.1148/radiol.2018180273 · 2018 · External reference
Diffusion-weighted imaging in identifying breast cancer pathological response to neoadjuvant chemotherapy: a meta-analysis
10.18632/oncotarget.23195 · 2017 · External reference
Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy
10.1016/j.ejrad.2013.10.023 · 2014 · External reference
The diagnostic performance of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in evaluating the pathological response of breast cancer to neoadjuvant chemotherapy: a meta-analysis
10.1016/j.ejrad.2021.109931 · 2021 · External reference
Comparison of diffusion-weighted and contrast-enhanced MRI for monitoring response to neoadjuvant therapy in breast cancer
10.1007/s00330-025-11640-y · 2025 · External reference
Diffusion-weighted imaging of the breast-a consensus and mission statement from the EUSOBI International Breast Diffusion-Weighted Imaging working group
10.1007/s00330-019-06510-3 · 2020 · External reference
Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of American pathologists guideline update
10.1200/jco.22.02864 · 2023 · External reference
Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
10.1093/annonc/mdt303 · 2013 · External reference
Differences in breast cancer survival by molecular subtypes in the United States
10.1158/1055-9965.epi-17-0627 · 2018 · External reference
Molecular portraits of human breast tumours
10.1038/35021093 · 2000 · External reference
Clinico-pathologic predictors of patterns of residual disease following neoadjuvant chemotherapy for breast cancer
10.1038/s41379-020-00714-5 · 2021 · External reference
Breast cancer subtype influences the accuracy of predicting pathologic response by imaging and clinical breast exam after neoadjuvant chemotherapy
10.21873/anticanres.11114 · 2016 · External reference
Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer
10.1016/j.phrs.2020.104683 · 2020 · External reference
Electroacupuncture facilitates vascular normalization by inhibiting Glyoxalase1 in endothelial cells to attenuate glycolysis and angiogenesis in triple-negative breast cancer
10.1016/j.canlet.2024.217094 · 2024 · External reference
